142663-83-0

Upstream product

• 4441-59-2 4-cyclohexyl-butylamine 
• 142757-98-0 3-{2-[(1S,2R,3S,4R)-3-(4-Chlorocarbonyl-oxazol-2-yl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-propionic acid methyl ester 
• 130776-16-8 [(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester 
• 142663-81-8 <1S-(1α,2α,3α,(R^*),4α)>-2-<<3-<<<2-<(4-cyclohexylbutyl)amino>-1-(hydroxymethyl)-2-oxoethyl>amino>carbonyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 
• 133027-60-8 Acetic acid (1R,2R,3R,4S)-3-(2-{3-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl ester 
• 135682-55-2 [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol 
• 142757-90-2 [1S-(1α,2α,3α,4α)]-2-[[3-[(Acetyloxy)methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid 
• 135682-53-0 <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid, methyl ester 
• 142758-00-7 3-[2-((1S,2R,3R,4R)-3-Hydroxymethyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-propionic acid 
• 404575-34-4 7-oxabicyclo<2.2.1>heptane tetrahydrofuranol 
• 91342-30-2 4-cyclohexyl-1-butanamine hydrochloride 
• 13214-66-9 4-phenyl-1-butylamine 
• 142757-92-4 <1S-(1α,2α,3α,4α)>-2-<<3-<<<1-(hydroxymethyl)-2-oxo-2-(phenylmethoxy)ethyl>amino>carbonyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 
• 135682-54-1 <1S-(1α,2α,3α,(S^*),4α)>-α-<2-<3-<oxy>propyl>phenyl>-7-oxabicyclo<2.2.1>heptane-2,3-dimethanol 

Downstream Products

• 139067-88-2 SQ 33961 
• 142663-78-3 <1S-(1α,2α,3α,4α)>-2-<<3-<4-<<(4-cyclohexylbutyl)amino>thiomethyl>-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 
• 149079-66-3 3-(2-{(1S,2R,3S,4R)-3-[4-(4-Cyclohexyl-butylcarbamoyl)-oxazol-2-yl]-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl}-phenyl)-propionic acid benzyl ester 
• 149079-67-4 2-{(1R,2S,3R,4S)-3-[2-(2-Benzyloxycarbonyl-ethyl)-benzyl]-7-oxa-bicyclo[2.2.1]hept-2-yl}-oxazole-4-carboxylic acid 4-cyclohexyl-butyl ester 
• 149117-75-9 <1S-(1α,2α,3α,4α)>-2-<<3-<4-<<(4-cyclohexylbutyl)amino>carbonyl>-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid ethyl ester 

Relevant academic research and scientific papers

7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasospastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is O, if Z is STR3 then Y cannot be O, and when Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 -5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.

Interphenylene 7-Oxabicycloheptane Oxazoles. Highly Potent, Selective, and Long-Acting Thromboxane A2 Receptor Antagonists

A series of interphenylene 7-oxabicycloheptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo.Examination of the carboxyl side chain indicated that the

7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasopastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is 0, if Z is STR3 then Y cannot be O, and Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 --5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.